Project Grant R01HL180740
Award Date 9/2/25
Completion Date 5/31/29
Dollars Obligated $549K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Illinois, USA
Similar Awards
- This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Federal Grant Program CFDA 93.837 - Cardiovascular Diseases Research, will support research to define cellular pathways that regulate lipid flux and elucidate their impact on cardiovascular disease. The $773,259 award, with a project period from December 2024 to November 2028, will enable the University of California, Los Angeles (UCLA) to: 1) Identify novel cholesterol-responsive proteins in the...
- This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $1,102,500 in funding to the University of California, Los Angeles (UCLA) from August 2025 through April 2032. The objective of the project is to address persistent problems in intravascular triglyceride metabolism, which can lead to higher levels of atherogenic lipoproteins and increased risk of coronary heart disease. The project builds on the awardee's prior...
- The University of Texas Southwestern Medical Center received a $772,275 Project Grant from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to conduct research on how endothelial cell scavenger receptor class B type I (SR-BI) is regulated and interacts with other proteins to drive LDL transcytosis and promote atherosclerosis. The award, effective August 25, 2025 through May 31, 2029, aims to determine the mechanisms by which hypercholesterolemia and...
- This $733,000 federal Project Grant award from the National Heart, Lung, and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837) supports research by Northwestern University to characterize the full spectrum of apolipoprotein post-translational modifications (PTMs) in human plasma and quantify their associations with upstream factors like adiposity and insulin resistance, as well as downstream impacts on atherogenic lipid levels and coronary heart disease events. The...
- This federal Project Grant award for $603,632, provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under CFDA 93.847 Diabetes, Digestive, and Kidney Diseases Extramural Research, aims to define the role of the PLA2G12B protein in regulating the assembly, plasma levels, metabolism, and cardiovascular disease risk of apolipoprotein B (apoB)-containing lipoproteins. The primary grantee, The Johns Hopkins University, will leverage novel tools to investigate how...
- This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) is funding research at the University of Arizona to investigate whether and how the hepatocyte protein TMEM141 regulates lipoprotein metabolism and atherosclerosis. The $744,453 award, which runs from August 1, 2025 through May 31, 2029, will utilize genetically modified mouse models and state-of-the-art techniques to study the role of TMEM141 in lipid and lipoprotein...
- This Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $787,267 to Yale University from January 1, 2025 to November 30, 2028 to conduct research aimed at determining whether genetic deletion of the DHCR24 enzyme in macrophages or hepatocytes can attenuate the progression of atherosclerosis. The project will exploit novel animal models and cutting-edge genomic and metabolomic technologies to evaluate the therapeutic...
- The National Heart Lung and Blood Institute (NHLBI), under CFDA 93.837 Cardiovascular Diseases Research program, awarded a $129,600 Project Grant to Weill Medical College of Cornell University. The grant, with an award date of Sep 5, 2025 and an ultimate completion date of Aug 31, 2027, supports research to elucidate the molecular mechanisms of macrophage foam cell formation in the development of atherosclerotic plaques. The research aims to investigate the role of cholesterol transport proteins...
- The National Heart, Lung, and Blood Institute (NHLBI) has awarded a $126,309 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Children's Hospital Medical Center in Cincinnati, Ohio. This 2-year research project, awarded on June 16, 2025, aims to characterize the functional role of a novel cardiac and adipose-enriched microprotein called NRAC and its involvement in lipid droplet biogenesis and lipid metabolism within the cardiovascular system. The research will...
- This Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) totaling $706,220.00 supports research to elucidate the role of the nuclear pore protein NUP93 in regulating endothelial cell function and vascular health. The research aims to investigate how phosphorylation of NUP93 by the AKT signaling pathway impacts YAP localization and endothelial inflammation, as well as the in vivo importance of NUP93 phosphorylation in...